Why the study?
Does ticagrelor improve safety and efficacy compared to clopidogrel in East Asian patients with acute coronary syndrome?
Does ticagrelor improve safety and efficacy compared to clopidogrel in East Asian patients with acute coronary syndrome?
In an East Asian ACS population, ticagrelor did not significantly improve safety or efficacy compared to clopidogrel, though results were limited by small sample size and low event rates.
Answers are grounded in this paper and cite their sources.
No significant ticagrelor benefit over clopidogrel in East Asian ACS; reinforces weak evidence against superiority in this population.
In ACS patients from Japan, Taiwan and South Korea, event rates of primary safety and efficacy endpoints were higher, albeit not significantly, in ticagrelor-treated patients compared with clopidogrel-treated patients. This observation could be explained by the small sample size, imbalance in clinical characteristics and low number of events in the PHILO population.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: